BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 24112455)

  • 1. A model to predict antiviral treatment in HBeAg negative chronic hepatitis B with alanine aminotransferase≤2 upper limit of normal.
    Gao S; Fan YC; Zhao J; Sun FK; Han J; Zhao ZH; Wang K
    Liver Int; 2014 Aug; 34(7):e229-37. PubMed ID: 24112455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A noninvasive model to predict liver histology in HBeAg-positive chronic hepatitis B with alanine aminotransferase ≤ 2upper limit of normal.
    Gao S; Li XY; Fan YC; Sun FK; Han LY; Li F; Ji XF; Wang K
    J Gastroenterol Hepatol; 2017 Jan; 32(1):215-220. PubMed ID: 27207016
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Accuracy of international guidelines for identifying significant fibrosis in hepatitis B e antigen--negative patients with chronic hepatitis.
    Sanai FM; Babatin MA; Bzeizi KI; Alsohaibani F; Al-Hamoudi W; Alsaad KO; Al Mana H; Handoo FA; Al-Ashgar H; Alghamdi H; Ibrahim A; Aljumah A; Alalwan A; Altraif IH; Al-Hussaini H; Myers RP; Abdo AA
    Clin Gastroenterol Hepatol; 2013 Nov; 11(11):1493-1499.e2. PubMed ID: 23811251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy of entecavir in chronic hepatitis B patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage.
    Wu IC; Lai CL; Han SH; Han KH; Gordon SC; Chao YC; Tan CK; Sievert W; Tanwandee T; Xu D; Neo BL; Chang TT
    Hepatology; 2010 Apr; 51(4):1185-9. PubMed ID: 20044806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is there a meaningful serum hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?
    Papatheodoridis GV; Manesis EK; Manolakopoulos S; Elefsiniotis IS; Goulis J; Giannousis J; Bilalis A; Kafiri G; Tzourmakliotis D; Archimandritis AJ
    Hepatology; 2008 Nov; 48(5):1451-9. PubMed ID: 18924246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of tenofovir disoproxil fumarate in hepatitis B e antigen-positive patients with normal levels of alanine aminotransferase and high levels of hepatitis B virus DNA.
    Chan HL; Chan CK; Hui AJ; Chan S; Poordad F; Chang TT; Mathurin P; Flaherty JF; Lin L; Corsa A; Gaggar A; Subramanian GM; McHutchison JG; Lau G; Lee S; Gane EJ
    Gastroenterology; 2014 May; 146(5):1240-8. PubMed ID: 24462735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreasing hepatitis B viral load is associated with a risk of significant liver fibrosis in hepatitis B e antigen positive chronic hepatitis B.
    Xie Q; Hu X; Zhang Y; Jiang X; Li X; Li J
    J Med Virol; 2014 Nov; 86(11):1828-37. PubMed ID: 25145769
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Viral load and alanine aminotransferase correlate with serologic response in chronic hepatitis B patients treated with entecavir.
    Wang CC; Tseng KC; Peng CY; Hsieh TY; Lin CL; Su TH; Tseng TC; Hsu CS; Lin HH; Kao JH
    J Gastroenterol Hepatol; 2013 Jan; 28(1):46-50. PubMed ID: 22989322
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of treatment requirement in HBeAg-negative chronic hepatitis B patients with persistently normal alanine aminotransferase and high serum HBV DNA levels.
    Ormeci A; Aydın Y; Sumnu A; Baran B; Soyer OM; Pınarbasi B; Gokturk S; Gulluoglu M; Onel D; Badur S; Akyuz F; Karaca C; Demir K; Besisik F; Kaymakoglu S
    Int J Infect Dis; 2016 Nov; 52():68-73. PubMed ID: 27619844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of relationship between histopathological, serological and biochemical parameters in patients with chronic hepatitis B infection.
    Diktas H; Karacaer Z; Özturk II; Cicek H
    Postgrad Med J; 2016 Dec; 92(1094):693-696. PubMed ID: 27170311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Is it necessary to delay antiviral therapy for 3-6 months to anticipate HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B in endemic areas of HBV genotype C?
    Song BC; Cho YK; Jwa H; Choi EK; Kim HU; Song HJ; Na SY; Boo SJ; Jeong SU
    Clin Mol Hepatol; 2014 Dec; 20(4):355-60. PubMed ID: 25548741
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Chronic hepatitis B virus (HBV) infection: usefulness of the combination of HBeAg and ALT determination to predict a high HBV-DNA level and therefore the necessity of referral to a specialist for possible antiviral treatment].
    Veldhuijzen IK; Mostert MC; Niesters HG; Richardus JH; de Man RA
    Ned Tijdschr Geneeskd; 2008 Jun; 152(25):1426-30. PubMed ID: 18624006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatitis B virus DNA level predicts hepatic decompensation in patients with acute exacerbation of chronic hepatitis B.
    Jeng WJ; Sheen IS; Liaw YF
    Clin Gastroenterol Hepatol; 2010 Jun; 8(6):541-5. PubMed ID: 20298811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significant hepatic histopathology in chronic hepatitis B patients with serum ALT less than twice ULN and high HBV-DNA levels in Indonesia.
    Lesmana CR; Gani RA; Hasan I; Simadibrata M; Sulaiman AS; Pakasi LS; Budihusodo U; Krisnuhoni E; Lesmana LA
    J Dig Dis; 2011 Dec; 12(6):476-80. PubMed ID: 22118698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A higher alanine aminotransferase level correlates with earlier hepatitis B e antigen seroconversion in lamivudine-treated chronic hepatitis B patients.
    Tseng TC; Liu CJ; Wang CC; Chen PJ; Lai MY; Kao JH; Chen DS
    Liver Int; 2008 Aug; 28(7):1034-41. PubMed ID: 18492018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of liver histological changes and a sustained virological response to peginterferon among chronic hepatitis B e antigen-positive patients with normal or minimally elevated alanine aminotransferase levels.
    Chen J; Xu CR; Xi M; Hu WW; Tang ZH; Zang GQ
    J Viral Hepat; 2017 Jul; 24(7):573-579. PubMed ID: 28107601
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spontaneous increases in alanine aminotransferase levels in asymptomatic chronic hepatitis B virus-infected patients.
    Kumar M; Chauhan R; Gupta N; Hissar S; Sakhuja P; Sarin SK
    Gastroenterology; 2009 Apr; 136(4):1272-80. PubMed ID: 19208347
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term continuous entecavir therapy in nucleos(t)ide-naïve chronic hepatitis B patients.
    Ono A; Suzuki F; Kawamura Y; Sezaki H; Hosaka T; Akuta N; Kobayashi M; Suzuki Y; Saitou S; Arase Y; Ikeda K; Kobayashi M; Watahiki S; Mineta R; Kumada H
    J Hepatol; 2012 Sep; 57(3):508-14. PubMed ID: 22659518
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictive value of interferon-gamma inducible protein 10 kD for hepatitis B e antigen clearance and hepatitis B surface antigen decline during pegylated interferon alpha therapy in chronic hepatitis B patients.
    Wang Y; Zhao C; Zhang L; Yu W; Shen C; Wang W; Zhen Z; Zhou J
    Antiviral Res; 2014 Mar; 103():51-9. PubMed ID: 24418572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Histologic evidence of active liver injury in chronic hepatitis B patients with normal range or minimally elevated alanine aminotransferase levels.
    Hu KQ; Schiff ER; Kowdley KV; Min AD; Shiffman ML; Lee WM; Goodman ZD; Dau LO; Peschell KJ; Fagan EA; Flaherty JF
    J Clin Gastroenterol; 2010 Aug; 44(7):510-6. PubMed ID: 20179614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.